| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
|
Ann Oncol
|
2012
|
3.06
|
|
2
|
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
|
Ann Oncol
|
2010
|
2.49
|
|
3
|
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer.
|
Ann Oncol
|
2012
|
2.38
|
|
4
|
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.
|
Ann Oncol
|
2007
|
1.90
|
|
5
|
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer.
|
Ann Oncol
|
2010
|
1.63
|
|
6
|
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.
|
Ann Oncol
|
2014
|
1.31
|
|
7
|
Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
|
Br J Cancer
|
2008
|
1.27
|
|
8
|
[Prevention, diagnosis, therapy, and follow-up of lung cancer].
|
Pneumologie
|
2010
|
1.14
|
|
9
|
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
|
Ann Oncol
|
2005
|
1.14
|
|
10
|
Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer.
|
Eur Respir J
|
2006
|
1.06
|
|
11
|
Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society.
|
Pneumologie
|
2010
|
1.06
|
|
12
|
SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results.
|
Ann Oncol
|
2004
|
1.04
|
|
13
|
Analysis of two human leukocyte antigen-linked polymorphic heat shock protein 70 genes in patients with severe sepsis.
|
Crit Care Med
|
1999
|
0.99
|
|
14
|
[Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version].
|
Pneumologie
|
2011
|
0.91
|
|
15
|
Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer.
|
Ann Oncol
|
2011
|
0.86
|
|
16
|
All-fiber three-path Mach-Zehnder interferometer.
|
Opt Lett
|
1996
|
0.86
|
|
17
|
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.
|
Ann Oncol
|
2010
|
0.85
|
|
18
|
Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study.
|
Ann Oncol
|
2012
|
0.83
|
|
19
|
Transforming growth factor-beta signaling leads to uPA/PAI-1 activation and metastasis: a study on human breast cancer tissues.
|
Pathol Oncol Res
|
2014
|
0.80
|
|
20
|
The Pstl polymorphism of the endotoxin-inducible heat-shock protein 70-2 gene does not affect messenger RNA level in human whole-blood cultures.
|
Intensive Care Med
|
2000
|
0.80
|
|
21
|
Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial.
|
Eur J Cancer
|
2004
|
0.79
|
|
22
|
[Joint statement of the German Respiratory Society and the German Roentgenological Society on the early detection of lung cancer by low-dose CT].
|
Pneumologie
|
2011
|
0.78
|
|
23
|
Synthesis of new carolacton derivatives and their activity against biofilms of oral bacteria.
|
Org Biomol Chem
|
2015
|
0.78
|
|
24
|
[New developments in treatment of non-small cell lung cancer].
|
Pneumologie
|
2013
|
0.75
|
|
25
|
[Non-small-cell carcinoma of the lung with invasive Aspergillus infection after chemotherapy].
|
Dtsch Med Wochenschr
|
2011
|
0.75
|
|
26
|
|
Pneumologie
|
2016
|
0.75
|
|
27
|
[Analysis of treatment outcomes in two patient cohorts (2004-2005 and 2007-2008) with limited and extensive disease small-cell lung cancer].
|
Pneumologie
|
2011
|
0.75
|
|
28
|
Carboplatin in small cell lung cancer.
|
Semin Oncol
|
1991
|
0.75
|
|
29
|
Carboplatin/etoposide/vincristine therapy in small cell lung cancer.
|
Oncology
|
1992
|
0.75
|
|
30
|
Combination chemotherapy with carboplatin, etoposide, and vincristine as first-line treatment in small-cell lung cancer.
|
J Clin Oncol
|
1992
|
0.75
|
|
31
|
Phase II and III studies with carboplatin in small cell lung cancer.
|
Semin Oncol
|
1992
|
0.75
|
|
32
|
Sex and age differences in preference for nonalcoholic drinks.
|
Psychol Rep
|
1969
|
0.75
|
|
33
|
[Treatment of non-small cell lung cancer].
|
Internist (Berl)
|
2011
|
0.75
|
|
34
|
[Chemotherapy of small cell bronchial cancer with a combination of carboplatin, vincristine and etoposide].
|
Pneumologie
|
1990
|
0.75
|